Use of alternative antiplatelet agents for clopidogrel hypersensitivity.

Use of alternative antiplatelet agents for clopidogrel hypersensitivity. Curr Vasc Pharmacol. 2018 Jul 29;: Authors: Ather A, Beavers CJ Abstract Clopidogrel is a widely used agent for secondary prevention of vascular events and is a cornerstone of dual antiplatelet therapy in patients with acute coronary syndrome (ACS) post coronary stent implantation. Hypersensitivity reactions to clopidogrel are well documented and may range from localized to systemic in presentation. This can lead to discontinuation of therapy, thus increasing the risk of vascular events. The authors have developed recommendations for potential alternative agents for the management of clopidogrel hypersensitivity reactions. Proposed strategies include treatment with an alternative P2Y12 inhibitor, cilostazol or warfarin. PMID: 30058492 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30058492?dopt=Abstract

Source: Current Vascular Pharmacology - July 29, 2018 Category: Drugs & Pharmacology Authors: Ather A, Beavers CJ Tags: Curr Vasc Pharmacol Source Type: research